false 0001446847 0001446847 2024-11-06 2024-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to 

Section 13 or 15(d) of the 

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

November 6, 2024

 

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34620   04-3404176
(State or other jurisdiction       (I.R.S. Employer
of incorporation)   (Commission File Number)   Identification Number)

 

100 Summer Street, Suite 2300        
Boston, Massachusetts       02110
(Address of principal        
executive offices)       (Zip code)

 

(617) 621-7722

(Registrant’s telephone number,

including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value IRWD Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 6, 2024, Andrew Davis notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Business Officer, effective November 22, 2024.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ironwood Pharmaceuticals, Inc.

 

Dated: November 12, 2024 By: /s/ Sravan K. Emany
    Name: Sravan K. Emany
    Title: Senior Vice President, Chief Operating Officer and Chief Financial Officer

 

 

 

v3.24.3
Cover
Nov. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 06, 2024
Entity File Number 001-34620
Entity Registrant Name IRONWOOD PHARMACEUTICALS, INC.
Entity Central Index Key 0001446847
Entity Tax Identification Number 04-3404176
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Summer Street
Entity Address, Address Line Two Suite 2300
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 617
Local Phone Number 621-7722
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.001 par value
Trading Symbol IRWD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Ironwood Pharmaceuticals (NASDAQ:IRWD)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Ironwood Pharmaceuticals
Grafico Azioni Ironwood Pharmaceuticals (NASDAQ:IRWD)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Ironwood Pharmaceuticals